The Xenotransplantation Market Size was valued at USD 13.6 billion in 2023. The Xenotransplantation market industry is projected to grow from USD 14.7 billion in 2024 to USD 26.3 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.60% during the forecast period (2024 - 2032). The growing prevalence of organ failure and the increase in surgeries are the primary drivers propelling the market's expansion.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Tissue donation is when tissues in the body (e.g., skin, corneas, bone) are taken out from one individual and relocated into someone else. The development of the portion is connected with the rising number of transplantation systems, for example, cochlear, heart valves, bone marrow, and delicate muscular tissues. An expected 30,000 tissue donors give roughly 1.75 million life-saving and life-further developing tissue transfers every year, as indicated by a March 2022 study from the Relationship of Organ Obtainment Association. Expanded tissue transplantation is expected to drive the market CAGR throughout the projected period.
Furthermore, the number of transplant surgeries for kidney, liver, heart, lungs, and tissues is predicted to rise as a result of advancements in transplantation technology and the introduction of new items by manufacturers. For example, in July 2021, Bioventus Inc. introduced OSTEOAMP SELECT Flowable, a flowable allograft bone graft replacement solution designed for a range of patient operations, such as foot and ankle fusion, cervical spine fusion, and lumbar spine fusion. Moreover, market expansion is facilitated by alliances, mergers, and acquisitions. For example, Orthofix Medical and MTF Biologics extended and renewed their cooperation agreement in May 2022. In addition to an expansion agreement to create a demineralized bone matrix (DBM) that Orthofix would sell under the Legacy brand name, the cooperation extends Orthofix's exclusive marketing rights to the Trinity allograft line through 2032.
Genetic engineering permits researchers to modify giver animals to deliver organs that are more viable with the human immune system. By altering explicit genes related to immune acknowledgment, scientists can decrease the risk of rejection and further develop graft endurance rates. By means of genetic modification, it is possible to modify pigs such that their cells express human proteins on their surface, therefore decreasing the probability of immune reaction and failure upon transplantation into humans. Preclinical research has demonstrated the potential of this strategy, which is moving toward clinical trials.
Growth prospects for the industry will be abundant due to the growing need for organ transplants and the possibility of xenotransplantation as a remedy. The Global Observatory On Donation and Transplantation, for example, reports that in 2021, over 144,302 organ transplant operations were carried out. With 92,532 operations performed globally, kidney transplants have the largest proportion. Long waiting lists and high death rates are also caused by the huge demand for organ transplants and the lack of available organ donors. Thus driving the Xenotransplantation market revenue.
The Xenotransplantation Market segmentation, based on types, includes organ preservation solutions, transplant diagnostics, and tissue products. In 2023, the organ preservation segment dominated the market. The advancement of novel organ conservation innovations, like hypothermic machine perfusion and normothermic perfusion, drives interest in particular safeguarding arrangements custom-made for these procedures. These advancements offer benefits over customary cold stockpiling techniques and require viable preservation solutions.
The tissue products category is anticipated to be the fastest growing. Xenogeneic tissues play a part in regenerative medication and tissue design applications. Tissue items like scaffolds, grids, and bioengineered builds derived from xenogeneic sources are utilized to help tissue repair, recovery, and substitution in different remedial settings.
Based on application, the Xenotransplantation Market segmentation includes heart, kidney, and other organs. In 2023, the kidney category generated the most income. Kidney transplantation is one of the most widely recognized organ transplant techniques around the world. Be that as it may, the interest in giver kidneys far surpasses the supply of accessible organs from human contributors. Xenotransplantation offers a potential solution for addressing the determined shortage of human kidneys for transplantation. Xenotransplantation research, including kidneys from hereditarily changed pigs, is effectively sought after in preclinical settings. Concentrates on a plan to assess the security, adequacy, and long-term outcomes of xenogeneic kidney transplantation in animal models, with the intention of moving forward with clinical studies.
The Xenotransplantation heart segment market is anticipated to grow fastest during the forecast period. Clinical preliminaries examining xenogeneic heart transplantation are in the beginning phases of advancement. These preliminaries plan to assess the safety, feasibility, and initial efficacy of xenotransplantation in human beneficiaries. Administrative endorsement and moral contemplations are key elements in progressing clinical preliminaries.
Figure 1: Xenotransplantation Market by Application, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World by region. The North American Xenotransplantation market will dominate this market. Rising rates of persistent diseases, for illustration, end-stage renal illness, cardiovascular breakdown, and liver failure in the U.S., are anticipated to impact business development decidedly. Moreover, the lack of organs for transplantation is another element expanding interest in xenotransplantation. Further, high interest in innovative work activities, government drives, and beneficial rules and regulations will support novel developments and progressions in xenotransplantation.
Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: XENOTRANSPLANTATION MARKET SHARE BY REGION 2023 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe's Xenotransplantation market accounts for the second-largest market share. Europe is well-equipped for research, driving academic organizations, research focuses, and biotechnology organizations that are effectively engaged with xenotransplantation research. This establishment upholds advancement and speeds up the improvement of novel treatments. Further, the German Xenotransplantation market held the largest market share, and the UK Xenotransplantation market was the fastest-growing market in the European region.
The Asia-Pacific Xenotransplantation Market is expected to grow at the fastest CAGR from 2024 to 2032. Patients in Asia Pacific nations are progressively looking for cutting-edge clinical medicines, including organ transplantation. Xenotransplantation offers a desire to patients who face significant delays for traditional organ transfers or have restricted access to donor organs. Moreover, China’s Xenotransplantation market held the largest market share, and the Indian Xenotransplantation market was the fastest-growing market in the Asia-Pacific region.
The industry's leading players will keep spending a lot of money on research and development to increase their product lines, which will propel the Xenotransplantation market's growth. Contractual agreements, mergers and acquisitions, increased investments, collaboration with other companies, and the production of new products are examples of significant market developments. To increase their worldwide reach, market players also take part in a variety of strategic initiatives. In order to survive and expand in a more competitive and dynamic market, the Xenotransplantation industry must offer reasonably priced products and services.
One of the main strategies manufacturers use in the worldwide Xenotransplantation market is local manufacturing, which expands the market sector and helps customers by lowering operating costs. The Xenotransplantation industry has recently provided some of the largest medical advantages. Major players in the Xenotransplantation market, including Terumo Medical Corporation, Astellas Pharma, Inc., Preservation Solutions, Inc., eGenesis, Inc., F. Hoffmann-La Roche Ltd., OrganOX Limited, TransMedic, Pte. Ltd., Novartis AG, Bio-Med Pvt. Ltd., Transplant Biomedical, Organ Recovery Systems, Veloxis Pharmaceuticals, Inc., United Therapeutics Corporation, Pfizer, Inc., and others, are making investments in R&D activities in an effort to boost market demand.
United Therapeutics Corp. creates and popularizes inventive drug items for the treatment of cardiovascular problems, especially aspiratory blood vessel hypertension and infectious sicknesses. The organization's items consist of prostacyclin analogs, including Remodulin (treprostinil) infusion, Tyvaso (treprostinil)inhalation solution, and Orenitram (treprostinil). Adcirca (tadalafil) is a phosphodiesterase type 5 (PDE-5) inhibitor, and Unituxin (dinutuximab), a monoclonal immune response for oncologic applications, are different items. Its item candidates incorporate monoclonal antibodies (mAbs), glycobiology antiviral specialists, and cell-based treatments. The organization likewise creates engineered lungs for transplantation in the pre-clinical stage. In October 2023, United Therapeutics Enterprise, a US-based biotechnology organization, procured Miromatrix Clinical for $91 million. This essential procurement is expected to extend United Therapeutics' existing organ creation drives, which incorporate xenotransplantation, three-dimensional bioprinting, x-vivo lung perfusion, and regenerative medication procedures. Miromatrix Clinical, situated in the US, is an improvement-stage organization known for its completely implantable fabricated kidney item.
Novartis AG is a medical organization that spotlights the revelation, improvement, production, and promotion of solutions, conventional drugs, and eye care products. It provides medications for the treatment of malignant growth, cardiovascular illnesses, dermatological circumstances, neurological problems, ophthalmic and respiratory sicknesses, hematologic illnesses, strong cancers, invulnerable issues, and diseases, among others. Novartis conducts research in different illness regions through the BioMedical Exploration division.
April 2022: eGenesis teamed up with Karius, the main infectious illness diagnostics supplier. This collaboration aimed to foster infectious illness diagnostics for xenotransplantation. Such drives fortify the improvement abilities of the two organizations in the substantial market.
January 2022: United Therapeutics Partnership (UT), a public advantage enterprise, presented the world's first recipient of an investigational hereditarily changed xenotransplant organ, UT's UHeart. This has been intended to give organs to patients unfit to get human organ donations, offering a competitive edge to the firm.
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 13.6 Billion |
| Market Size 2024 | USD 14.7 Billion |
| Market Size 2032 | USD 26.3 Billion |
| Compound Annual Growth Rate (CAGR) | 8.60% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2019-2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Types, Applications, and Regions |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Terumo Medical Corporation, Astellas Pharma, Inc., Preservation Solutions, Inc., eGenesis, Inc., F. Hoffmann-La Roche Ltd., OrganOX Limited, TransMedic, Pte. Ltd., Novartis AG, Bio-Med Pvt. Ltd., Transplant Biomedical, Organ Recovery Systems, Veloxis Pharmaceuticals, Inc., United Therapeutics Corporation, and Pfizer, Inc. |
| Key Market Opportunities | · Increasing rates of excessive alcohol consumption and developing novel therapies |
| Key Market Dynamics | · Growing prevalence of organ failure and increase in surgeries |
Frequently Asked Questions (FAQ) :
The Xenotransplantation Market size was valued at USD 13.6 Billion in 2023.
The global market is projected to grow at a CAGR of 8.60% during the forecast period, 2024-2032.
North America had the largest share of the global market
The key players in the market are Terumo Medical Corporation, Astellas Pharma, Inc., Preservation Solutions, Inc., eGenesis, Inc., F. Hoffmann-La Roche Ltd., OrganOX Limited, TransMedic, Pte. Ltd., Novartis AG, Bio-Med Pvt. Ltd., Transplant Biomedical, Organ Recovery Systems, Veloxis Pharmaceuticals, Inc., United Therapeutics Corporation, and Pfizer, Inc.
The Organ Preservation Solutions category dominated the market in 2023.
The kidney category had the largest share of the global market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
